When the immune system has become your enemy

A unique treatment for introducing immunological tolerance

Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues.

Link to: Idogen´s technologyLink to: Stock informationLink to: Upcoming eventsLink to: Presentations and Interviews

Idogen´s technology enables development of tolerogenic cell therapy in a number of areas

Read more about our therapeutic areas:

Idogen develops tolerogenic cell therapy

Individualised treatment for each patient

SUBSCRIBE

Which information would you like to subscribe to?
Which information would you like to subscribe to?

TWITTER

Idogen AB (”Idogen”) har idag offentliggjort årsredovisningen för 2019.

Årsredovisningen finns tillgänglig på hemsidan https://www.idogen.com/investerare/finansiella-rapporter/

BioStock-intervju med Professor Jolanda de Vries, Radboud University Medical Center https://news.cision.com/se/idogen/r/biostock-intervju-med-professor-jolanda-de-vries--radboud-university-medical-center,c3082114

Load More...

Idogen AB   |   Medicon Village   |   Scheelevägen 2   |   SE-223 81 Lund   |  Sweden   |  E-mail: info at idogen dot com

This project has received funding from the European Union’s Horizon 2020 research and innovation programme.